Cell and Gene Therapy Strategic Roundup | June 24–July 29, 2026
Cell and Gene Therapy Strategic Roundup exploring Developments and Competitive…
Neuroscience Strategic Roundup | June17–July 21, 2026
Strategic Developments and Competitive Shifts in Neuroscience Coverage Period:…
Immunology Strategic Roundup | June 9–July 14, 2026
Key Strategic Developments and Competitive Shifts in Immunology Coverage: June…
Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief
Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…
Warburg Pincus PANTHERx Rare Acquisition | Lucid Diligence Brief
Warburg Pincus to acquire control of PANTHERx Rare, backing expansion of the…
SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Vedana Therapeutics has emerged from stealth with $46 million in Series A…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…